Table 4 Base case results
Overview of base case results comparing SLIT allergen and SCIT allergoid immunotherapy | ||||||
|---|---|---|---|---|---|---|
Discounted and undiscounted total QALYs per treatment after a time horizon of 9Â years | ||||||
| Â | Discounted | Undiscounted | Â | Â | Â | Â |
5-grass tablet | 7.316 | 8.207 | Â | Â | Â | Â |
Allergoid mix | 7.280 | 8.166 | Â | Â | Â | Â |
Symptomatic tx | 7.235 | 8.116 | Â | Â | Â | Â |
Absolute and relative distribution of total undiscounted costs over individual cost components after 9Â years | ||||||
| Â | 5-grass tablet | Allergoid mix | Symptomatic | |||
| Â | Cost | Perc. | Cost | Perc. | Cost | Perc. |
Visits (e.g. Dermatologist) | € 267 | 15.0% | € 299 | 22.9% | € 227 | 62.4% |
Injection/control | € 4 | 0.2% | € 69 | 5.2% | € 0 | 0.0% |
Diagnostics | € 21 | 1.2% | € 21 | 1.6% | € 0 | 0.0% |
Treatment costs | € 1,381 | 77.7% | € 809 | 61.8% | € 0 | 0.0% |
Other drugs costs | € 82 | 4.6% | € 86 | 6.6% | € 102 | 28.1% |
Asthma | € 23 | 1.3% | € 25 | 1.9% | € 34 | 9.5% |
Total | € 1,778 | 100% | € 1,308 | 100% | € 363 | 100.0% |
Discounted and undiscounted total costs per treatment and incremental costs after a time horizon of 9Â years | ||||||
| Â | Discounted | Undiscounted | Â | Â | ||
| Â | Total | Inc. vs. 5-grass tablet | Total | Inc. vs. 5-grass tablet | Â | Â |
5-grass tablet | € 1,707 |  | € 1,778 |  |  |  |
Allergoid mix | € 1,249 | € 458 | € 1,308 | € 470 |  |  |
Symptomatic tx | € 322 | € 1,385 | € 363 | € 1,415 |  |  |
Discounted and undiscounted incremental costs and ICERs after a time horizon of 9Â years | ||||||
| Â | Inc. Costs | Inc. QALYs | ICER | Â | Â | Â |
Discounted | Â | Â | Â | Â | Â | Â |
5-grass tablet vs. Allergoid mix | € 458 | 0.036 | € 12,593 |  |  |  |
5-grass tablet vs. Symptomatic tx | € 1,385 | 0.081 | € 17,007 |  |  |  |
Undiscounted | Â | Â | Â | Â | Â | Â |
5-grass tablet vs. Allergoid mix | € 470 | 0.041 | € 11,576 |  |  |  |
5-grass tablet vs. Symptomatic tx | € 1,415 | 0.090 | € 15,635 |  |  |  |